NCT02256475View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Tourette Syndrome
Interventions
DRUG

NBI-98854

Trial Locations (10)

Unknown

San Diego

Kissimmee

St. Petersburg

Naperville

St Louis

Lincoln

New York

Rochester

Petersburg

Kirkland

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY